Key Points Pharmaceutical giant Eli Lilly delivers strong financial results and has a deep lineup and pipeline. Much smaller Viking Therapeutics boasts several candidates whose progress could jolt its ...

Both Eli Lilly LLY and Merck MRK are major players in the U.S. pharmaceutical industry, developing and commercializing ...

In 2022, over 1 billion people were affected by obesity, driving innovation in therapeutic advancements. Emerging treatments focus on appetite control and metabolic pathways, with pharmaceutical ...

JPMorgan said Eli Lilly is enrolling about 500,000 new obesity drug patients per month, and maintains more than 60% share in ...

Eli Lilly, Summit Therapeutics, and Vertex Pharmaceuticals all have important ongoing clinical trials. Shares of these ...

Wall St. provides estimates for future stock prices of Eli Lilly from 2025 to 2030 based on projected revenue and net income.

Industry-Wide Tariffs Loom Over the Healthcare Sector. Here Are 2 Stocks That Can Weather the Storm.

Eli Lilly said it expects to release data from a late-stage trial on its next-generation weight loss drug retatrutide in 2025, a few months earlier than expected.

Eli Lilly (NYSE:LLY) is a pharmaceutical titan with an $815 billion market cap, putting it on track to be the next $1 trillion stock and the first healthcare company to do so. Trading at $852 per ...

Eli Lilly and Co. announced plans on Tuesday to acquire private biotechnology company San Francisco-based SiteOne Therapeutics Inc. in a deal worth up to $1 billion.

Zepbound and Eli Lilly's diabetes drug Mounjaro now make up over half of U.S. prescriptions for so-called GLP-1s, which mimic hormones to tamp down appetite and regulate blood sugar, according to ...